Heated Humidified Breathing Circuit Rewarming in Hypothermic Post Cardiopulmonary Bypass Patients.

July 2, 2020 updated by: Duke University
Hypothermia on admission to the intensive care unit (ICU) following cardiopulmonary bypass (CPB) is common. The investigators propose that rewarming hypothermic (≤ 35 C) patients admitted to the intensive care unit following procedures using CPB with heated humidified breathing circuits (HHBC) in addition to conventional forced air warming blankets will shorten time to normothermia. Secondarily it may shorten time to extubation, improve coagulopathy, and metabolic derangements seen with hypothermia.

Study Overview

Detailed Description

Hypothermia on admission to the intensive care unit (ICU) following cardiopulmonary bypass (CPB) is common. Cooling and rewarming during CPB and deep hypothermic circulatory arrest (DHCA) takes considerable time and contributes to the post-procedural coagulopathy and physiologic perturbations. Core body parts (trunk and head) rewarm more quickly than peripheral parts (extremities). After disconnecting from CPB the body is allowed to self equilibrate. The normal vasoconstriction response is impaired by the administered anaesthesia. Hence, heat distribution takes place from the warm core to the colder periphery. This causes an afterdrop: a decrease in the temperature of the core organs. After-drop may contribute to post-operative complications such as shivering, coagulopathy, increased myocardial stress, increased wound infections, metabolic acidosis, delayed extubation and prolonged ICU length of stay (LOS).

The use of the active warming via traditional methods (ie forced air warming blankets) and Heated Humidified breathing circuits (HHBC) via ANAPOD Heated Humidification System® (ANAPOD) may shorten time to normothermia. Secondarily it may shorten time to extubation, improve coagulopathy, and metabolic derangements seen with hypothermia.

Sample and Study Design- The investigators will prospectively collect data for 14 enrolled non-patients who will receive active warming via both forced air warming blankets and Heated Humidified breathing circuits (HHBC). Retrospective data will be obtained retrospectively for 28 matched patients from two years prior to initiation of the trial, who received warming only via forced air warming blankets.

Data Collection Plan- Data will be extracted and collected by the Duke Department of Anesthesiology IT analyst, who will review and extract information from the patient's chart via Epic/ Maestro Care, or manually if necessary.

Data Evaluation- Descriptive statistics will be used to evaluate patient demographics and clinical characteristics. Descriptive statistics will be summarized as mean ± (SD) or median (interquartile range) for continuous variables and group frequencies (%) for dichotomous or categorical variables.

As all patients are expected to achieve normothermia within the study period, the primary outcome of time to normothermia will be analyzed as a numeric outcome variable. Following validation of distributional assumptions the investigators will compare the time to normothermia between the two groups via t-test or Wilcoxon rank sum test as appropriate. It is expected that the patients will reach normothermia between 45 minutes and 6 hours after admission to the ICU.

By using a 2:1 matching ratio and a moderate level of variability (SD=1.3 hours) a study of 14 prospectively enrolled patients and 28 retrospectively matched patients would attain 82% power to detect a 1.25 hour difference between time to normothermia in the prospective group (active warming via traditional methods (ie forced air warming blankets) and Heated Humidified breathing circuits (HHBC) via ANAPOD Heated Humidification System® (ANAPOD), and the retrospective group (active warming via traditional methods (ie forced air warming blankets only) at alpha level 0.05.

Secondary numeric outcomes such as time to extubation, time to normal PH, and coagulopathy lab values will be analyzed by t-test or Wilcoxon rank sum test as appropriate. Differences in categorical outcomes between treatment groups will be analyzed via chi-square or fisher exact tests. As the patients will be matched on key confounders no further adjustment is expected to be necessary, so the moderate sample size should not limit the primary analysis. Potential subgroup analysis may be conducted in an exploratory analysis to determine if the treatment effect of ANAPOD warming is different by procedure type or patient/surgical characteristics.

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Durham, North Carolina, United States, 27710
        • Duke University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Admission to intensive care unit following surgical procedure involving cardiopulmonary bypass.
  • Admission temperature ≤ 35.0 C.

Exclusion Criteria:

  • Patients placed on extracorporeal membrane oxygenation intra-operatively, or during first 24 hours after ICU admission.
  • Any additional surgical procedures in the first 24 hours days after initial surgery e.g. Chest exploration for bleeding, Open Chest, Non-cardiac surgery such as colectomy for ischemic gut, etc.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HHBC and Forced Air Warming
Patients admitted to intensive care unit hypothermic (≤ 35 C) following surgical procedures involving cardiopulmonary bypass. Will be rewarmed with heated humidified breathing circuits (ANAPOD) and standard forced air warming blankets.

Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.

Forced air warming blankets will be set at 42C for duration of rewarming.

Other Names:
  • ANAPOD

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Normothermia
Time Frame: up to 24 hours post admission to intensive care unit
Core temperature normothermia defined as >=36.5 C.
up to 24 hours post admission to intensive care unit

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Extubation
Time Frame: up to 24 hours post admission to intensive care unit
Time from admission to time of extubation. Followup was truncated at 24 hours and if patient had not been extubated at that time they were assigned a value of 24 hours.
up to 24 hours post admission to intensive care unit
Coagulopathy as Measured by Need for Transfusion of Blood Product
Time Frame: 24 hours post admission to intensive care unit
Assessed via number of transfusions of red blood cells, fresh frozen plasma, platelets, cryoprecipitate.
24 hours post admission to intensive care unit
Metabolic Derangement as Measured by Time to Normal pH
Time Frame: up to 24 hours post admission to intensive care unit
Assessed via blood gas analysis. Normal pH defined as 7.35-7.45.
up to 24 hours post admission to intensive care unit
Number of Subjects With Abnormal Coagulopathy as Measured by Laboratory Assessment of Prothrombin Time
Time Frame: 24 hours post admission to intensive care unit
Laboratory assessment of Prothrombin Time with normal defined as 9.5-13.1 seconds.
24 hours post admission to intensive care unit
Number of Subjects With Abnormal Coagulopathy as Measured by Laboratory Assessment of INR
Time Frame: 24 hours post admission to intensive care unit
Laboratory assessment of international normalised ratio (INR) with normal defined as 0.9-1.1.
24 hours post admission to intensive care unit
Number of Subjects With Abnormal Coagulopathy as Measured by Laboratory Assessment of Act Partial Thromboplastin Time
Time Frame: 24 hours post admission to intensive care unit
Laboratory assessment of Act Partial Thromboplastin Time with normal defined as 26.8-37.1 seconds.
24 hours post admission to intensive care unit
Number of Subjects With Abnormal Coagulopathy as Measured by Laboratory Assessment of Fibrinogen.
Time Frame: 24 hours post admission to intensive care unit
Laboratory assessment of fibrinogen levels with normal defined as 213-435 mg/dL.
24 hours post admission to intensive care unit
Number of Subjects With Abnormal Coagulopathy as Measured by Laboratory Assessment of Platelet Count
Time Frame: 24 hours post admission to intensive care unit
Laboratory assessment of platelet count with normal defined as 150 - 450 x10ˆ9/L.
24 hours post admission to intensive care unit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Negmeldeen Mamoun, MD, Duke Univeristy Hospital Anesthesia Department

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2019

Primary Completion (Actual)

June 15, 2019

Study Completion (Actual)

June 15, 2019

Study Registration Dates

First Submitted

September 27, 2018

First Submitted That Met QC Criteria

October 3, 2018

First Posted (Actual)

October 5, 2018

Study Record Updates

Last Update Posted (Actual)

July 15, 2020

Last Update Submitted That Met QC Criteria

July 2, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypothermia

Clinical Trials on Heated Humidified Breathing Circuit and Forced Air Blanket

3
Subscribe